🔥ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1
🆙 @JCO_ASCO
☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC
🎙Dr. Lyudmila Bazhenova @HHorinouchi#LCSM@OncoAlert@Larvol
https://t.co/k4lOuFfjrl
🚨 cfRNA is Here — and It’s a Game Changer! 🧬🩸
@max_diehn et al., @Nature 2025
🔗 DOI: 10.1038/s41586-025-08834-1
👏 From one of our #ISLB awardees!
🔍 Key Highlights:
✅ RAREseq: A new method for ultrasensitive cfRNA profiling 💡
✅ cfRNA detects early-stage NSCLC with higher sensitivity than ctDNA 📈
✅ Reveals genetic & non-genetic resistance to EGFR TKIs in plasma 🧪
✅ Captures tumor-specific expression patterns beyond mutation status 🔬
✅ Enables real-time disease monitoring in patients on targeted therapy ⏱️
💡 cfRNA is poised to complement and even surpass ctDNA in key clinical settings.
@ChristianRolfo@ElJanLe@DrYukselUrun@UmbertoMalapel1@drgandara@MJOSESERRANO19
#LiquidBiopsy #cfRNA #NSCLC #EGFR #CancerDiagnostics #PrecisionOncology #ISLB 🚀
237 volte grazie: grazie agli anatomopatologi, ai biologi, ai biotecnologi, agli oncologi, agli infermieri, ai genetisti, ai tecnici di laboratori biomedici. Grazie a tutte e tutti voi! Ci vediamo l'anno prossimo a Napoli 🌋
#PMMP25 ➡️ #PMMP26@UmbertoMalapel1@FabioPagni1
This manuscript from the IASLC Pathology Committee proposes a combined histologic and molecular algorithm in categorizing multiple lung adenocarcinomas into SPLCs or IPMs, specifically that genomic profiling by NGS should be performed whenever possible. https://t.co/P9FHlTcqpB
🚀 È online il sito del gruppo PMMP della SIAPEC!
Punto di riferimento per la Patologia Molecolare e la Medicina di Precisione 🧬🔬
Scopri le nostre iniziative, raccomandazioni e collaborazioni!
🔗 Visita il sito: https://t.co/akelQkACOO
#PMMP#SIAPEC
Press release: phase III LAURA trial meets primary endpoint. Stage III #EGFR NSCLC post chemoradiation, indefinite osimertinib superior to placebo. No surprise - eager to see magnitude of benefit, patterns of relapse, OS trends, and crossover rate…
https://t.co/5BKEDnlSoH
Il programma di cure oncologiche a Niguarda Cancer Center riguarda anche i tumori rari, tra cui il sarcoma cardiaco: un raro tumore maligno che il team dell'@ospniguarda si occupa di trattare e studiare, grazie alla Fondazione.
Scopri di più https://t.co/Egj5DEghSw
Proud to share our case report#Acute promyelocytic leukemia with del(6)(p22) and atypical bcr2 PML::RARA fusion transcript: a case report. https://t.co/lHyPnovhxd
The use of NGS on DNA🧬 from tissue or liquid biopsies is now well established in the management of patients with cancer. In this Letter to the Editor, @ArBayle and coll. present the data from cases tested with both modalities in PRISM 🇫🇷
https://t.co/nzTbEDFfCE